AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatmen
July 10 2007 - 9:00AM
Business Wire
AVI BioPharma, Inc. (Nasdaq:AVII) announced today that its partner
Cook Medical has completed target patient enrollment and released
six-month follow-up data from a Phase II clinical trial known as
APPRAISAL. The trial, currently being held in Germany, was designed
to study the effect of the NEUGENE� antisense drug Resten-MP�, when
used in conjunction with the placement of one or more bare metal
stents, in the prevention of cardiovascular restenosis, the
narrowing of an artery following a cardiac procedure such as
angioplasty. �We are pleased with the progress our partner Cook
Medical has made with our NEUGENE in this trial,� said K. Michael
Forrest, interim chief executive officer of AVI. �We look forward
to continuing our collaboration with Cook Medical as they work to
commercialize our technology in the cardiology market.� Cook�s
release may be viewed on AVI�s website at www.avibio.com. About AVI
BioPharma AVI BioPharma develops therapeutic products for the
treatment of life-threatening diseases using third-generation
NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI�s
lead NEUGENE antisense compound is designed to target cell
proliferation disorders, including cardiovascular restenosis. In
addition to targeting specific genes in the body, AVI�s antiviral
program uses NEUGENE antisense compounds to combat disease by
targeting single-stranded RNA viruses, including West Nile virus,
hepatitis C virus, dengue virus, Ebola virus and influenza A virus.
AVI�s NEUGENE-based ESPRIT technology will initially be applied to
potential treatments for Duchenne muscular dystrophy. More
information about AVI is available on the company�s Web site at
http://www.avibio.com. About Cook Medical Cook Medical was the
first company to introduce interventional devices in the United
States. Today, the company participates in all global markets,
integrating device design, biopharma, gene and cell therapy and
biotech to enhance patient safety and improve clinical outcomes.
Cook won the prestigious Medical Device Manufacturer of the Year
for 2006 from Medical Device and Diagnostic Industry magazine. For
more information, visit www.cookmedical.com. �Safe Harbor�
Statement under the Private Securities Litigation Reform Act of
1995: The statements that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including, but not limited to, the results of
research and development efforts, the results of preclinical and
clinical testing, the effect of regulation by the FDA and other
agencies, the impact of competitive products, product development,
commercialization and technological difficulties, and other risks
detailed in the company�s Securities and Exchange Commission
filings.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024